Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
331-01-018 / 331-01-018 ISMRM Abstract

Nicotinamide riboside supplementation improves cerebral glucose metabolism in a mouse model of Alzheimer’s disease

Primary: Neuro - Alzheimer's Disease
Secondary: Preclinical Animal & in vitro MR - Small Animals
331-01-018 · Neuro Imaging and Metabolism · Monday, 11 May, 8:20 AM–10:10 AM · Roof Terrace
331-01-018 · Neuro Imaging and Metabolism · Monday, 11 May, 8:20 AM–10:10 AM · Roof Terrace
Keywords: Alzheimer's Disease Deuterium Metabolic Imaging Cerebral energy metabolism Therapy effect evaluation Nicotinamide riboside
Accepted
Anshuman Swain1, Narayan Datt Soni1,2,3,4, Sunil K Khokhar1,2,3,4, Bhavya Yendapalli, Dipak Roy1, Halvor Juul1,3, Abeer Mathur1,3, RAVI PRAKASH REDDY NANGA1,3, Mohammad Haris1,3,4, Ravinder Reddy1,2,3,4,5,6
1Department of Radiology, Center for Advanced Metabolic Imaging in Precision Medicine (CAMIPM), University of Pennsylvania, Philadelphia, United States of America
2Department of Radiology, University of Pennsylvania, Philadelphia, United States of America
3University of Pennsylvania, Philadelphia, United States of America
4Center for Advanced Metabolic Imaging in Precision Medicine, Philadelphia, United States of America
5Center for Advanced Metabolic Imaging in Precision Medicine, Center for Advanced Metabolic Imaging in Precision Medicine, Philadelphia, United States of America
6Center for Advanced Metabolic Imaging in Precision Medicine, University of Pennsylvania, Philadelphia, United States of America
Presenting Author: Blake A Benyard

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Xie N, Zhang L, Gao W, Huang C, Huber PE, Zhou X, et al. NAD(+) metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020;5(1):227. 10.1038/s41392-020-00311-7 [doi]
2. Wang X, He HJ, Xiong X, Zhou S, Wang WW, Feng L, et al. NAD(+) in Alzheimer's Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo. Front Cell Dev Biol. 2021;9:668491. 10.3389/fcell.2021.668491 [doi]
3. Campbell JM. Supplementation with NAD(+) and Its Precursors to Prevent Cognitive Decline across Disease Contexts. Nutrients. 2022;14(15). 10.3390/nu14153231 [doi]
4. Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging. 2013;34(6):1581-8. 10.1016/j.neurobiolaging.2012.12.005 [doi]
5. Wu CY, Kupferschmid AC, Chen L, McManus AJ, Kivisakk P, Galler JA, et al. Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment. Alzheimers Dement (N Y). 2025;11(1):e70023. 10.1002/trc2.70023 [doi]
6. Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L. Hypometabolism, Alzheimer's Disease, and Possible Therapeutic Targets: An Overview. Cells. 2023;12(16). 10.3390/cells12162019 [doi]
7. Soni ND, Swain A, Jacobs P, Juul H, Armbruster R, Nanga RPR, et al. In vivo assessment of beta-hydroxybutyrate metabolism in mouse brain using deuterium ((2) H) MRS. Magn Reson Med. 2023;90(1):259-69. 10.1002/mrm.29648 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/331-01-018